Joseph Pape

Array ( [id] => 17134821 [patent_doc_number] => 11136367 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => Multi-level specific targeting of cancer cells [patent_app_type] => utility [patent_app_number] => 16/704645 [patent_app_country] => US [patent_app_date] => 2019-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13401 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16704645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17236676 [patent_doc_number] => 11180548 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => Methods of neutralizing IL-8 biological activity [patent_app_type] => utility [patent_app_number] => 16/697310 [patent_app_country] => US [patent_app_date] => 2019-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 47 [patent_no_of_words] => 119104 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16697310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376360 [patent_doc_number] => 20200325202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => IL-2 MUTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/693741 [patent_app_country] => US [patent_app_date] => 2019-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15486 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16693741 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17029721 [patent_doc_number] => 11091526 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-17 [patent_title] => IL-2 muteins and uses thereof [patent_app_type] => utility [patent_app_number] => 16/693693 [patent_app_country] => US [patent_app_date] => 2019-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 15493 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16693693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17490464 [patent_doc_number] => 11279753 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-22 [patent_title] => Use of TGF-alpha polypeptide or anti-TGF-alpha antibodies for the treatment of diseases and disorders [patent_app_type] => utility [patent_app_number] => 16/693046 [patent_app_country] => US [patent_app_date] => 2019-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 21 [patent_no_of_words] => 18000 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16693046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060142 [patent_doc_number] => 11104729 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => Anti-IL-33 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/687257 [patent_app_country] => US [patent_app_date] => 2019-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 23846 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16687257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17342195 [patent_doc_number] => 20220008526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/293995 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16503 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17293995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18329271 [patent_doc_number] => 11634499 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-25 [patent_title] => Control of trace metals during production of anti-CD38 antibodies [patent_app_type] => utility [patent_app_number] => 16/682551 [patent_app_country] => US [patent_app_date] => 2019-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 55215 [patent_no_of_claims] => 77 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16682551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18128976 [patent_doc_number] => 11555175 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-17 [patent_title] => Cell culture methods and media comprising N-acetylcysteine [patent_app_type] => utility [patent_app_number] => 16/679713 [patent_app_country] => US [patent_app_date] => 2019-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 14431 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16679713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16999476 [patent_doc_number] => 11078267 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Method for treating lupus by administering an anti-IL-12 antibody [patent_app_type] => utility [patent_app_number] => 16/677120 [patent_app_country] => US [patent_app_date] => 2019-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 13 [patent_no_of_words] => 28756 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16677120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198636 [patent_doc_number] => 20210338730 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => Marrow Infiltrating Lymphocytes With Increased Clonality and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/284693 [patent_app_country] => US [patent_app_date] => 2019-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8728 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15454497 [patent_doc_number] => 20200040073 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => METHODS FOR ADMINISTERING ANTI-IL-5 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/660972 [patent_app_country] => US [patent_app_date] => 2019-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16660972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16956035 [patent_doc_number] => 11059877 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => Multivalent regulatory T cell modulators [patent_app_type] => utility [patent_app_number] => 16/655544 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 34 [patent_no_of_words] => 25769 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16655544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18518534 [patent_doc_number] => 11708415 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 [patent_app_type] => utility [patent_app_number] => 16/599709 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 9 [patent_no_of_words] => 18662 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 183 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16599709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15454503 [patent_doc_number] => 20200040076 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE [patent_app_type] => utility [patent_app_number] => 16/598011 [patent_app_country] => US [patent_app_date] => 2019-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34000 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16598011 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16703067 [patent_doc_number] => 10952980 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes [patent_app_type] => utility [patent_app_number] => 16/593689 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 19 [patent_no_of_words] => 18225 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16593689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17369955 [patent_doc_number] => 20220025007 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => NOVEL IMMUNOSUPPRESSIVE INTERLEUKIN 2 [patent_app_type] => utility [patent_app_number] => 17/416852 [patent_app_country] => US [patent_app_date] => 2019-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7579 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17416852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17207775 [patent_doc_number] => 11168134 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-09 [patent_title] => Methods of treating androgen deprivation therapy resistant prostate cancer [patent_app_type] => utility [patent_app_number] => 16/574828 [patent_app_country] => US [patent_app_date] => 2019-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 12 [patent_no_of_words] => 13696 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16574828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15618853 [patent_doc_number] => 20200079831 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-12 [patent_title] => HETERODIMERIC PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/571853 [patent_app_country] => US [patent_app_date] => 2019-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16571853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16468203 [patent_doc_number] => 20200369740 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/959312 [patent_app_country] => US [patent_app_date] => 2019-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21078 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16959312 [rel_patent_id] =>[rel_patent_doc_number] =>)